 Akers Biosciences Inc., a South Jersey medical device company that recently joined the race to develop a COVID-19 vaccine, plans to raise 4.6 million in a public stock sale. The Thorofare-based company is selling 766,667 shares of its common stock at a purchase price of 6.00 per share, according to documents filed with the Securities and Exchange Commission. Last month, Akers entered into an in-licensing and product development deal for a coronavirus vaccine candidate under development by Premas Biotech. 